55
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 16 , 23 , the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists
      Journal of the European Academy of Dermatology and Venereology
      Wiley

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Management of AE must consider the individual clinical variability of the disease; highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long-term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.

          Related collections

          Most cited references158

          • Record: found
          • Abstract: found
          • Article: not found

          Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.

          Atopic disease, including atopic dermatitis (eczema), allergy and asthma, has increased in frequency in recent decades and now affects approximately 20% of the population in the developed world. Twin and family studies have shown that predisposition to atopic disease is highly heritable. Although most genetic studies have focused on immunological mechanisms, a primary epithelial barrier defect has been anticipated. Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin barrier. Here we show that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis. These variants are carried by approximately 9% of people of European origin. These variants also show highly significant association with asthma occurring in the context of atopic dermatitis. This work establishes a key role for impaired skin barrier function in the development of atopic disease.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

              Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.
                Bookmark

                Author and article information

                Journal
                Journal of the European Academy of Dermatology and Venereology
                J Eur Acad Dermatol Venereol
                Wiley
                09269959
                May 2018
                May 2018
                April 20 2018
                : 32
                : 5
                : 657-682
                Affiliations
                [1 ]Department Dermatology and Allergy; Ludwig-Maximilian University; Munich Germany
                [2 ]Klinik Thalkirchner Straße; Munich Germany
                [3 ]Department of Dermatology; Centre Hospitalier Universitaire CHU Nantes; Nantes France
                [4 ]Department of Dermatology and Allergy; Christine Kühne-Center for Allergy Research and Education; University Bonn; Bonn Germany
                [5 ]Pediatric Dermatology Unit; Departments of Dermatology and Pediatrics; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
                [6 ]Department Dermatology; Aarhus University Hospital; Aarhus Denmark
                [7 ]European Federation of Allergy and Airways Diseases Patients’ Associations (EFA); Global Allergy and Asthma Patient Platform (GAAPP); Konstanz Germany
                [8 ]Department of Dermatology; University of Gießen and Marburg GmbH; Gießen Germany
                [9 ]Department of Psychosomatics and Psychotherapy; University of Gießen and Marburg GmbH; Gießen Germany
                [10 ]Department of Medicine; Section of Dermatology; University of Verona; Verona Italy
                [11 ]Pediatric Pneumology and Immunology; Universitätsmedizin Berlin; Berlin Germany
                [12 ]Centro di Specializzazione Regionale per lo Studio e la Cura delle Allergie e delle Intolleranze Alimentari presso l'Azienda Ospedaliera; Università di Padova; Padova Italy
                [13 ]Department of Dermatology; Medical University; Poznan Poland
                [14 ]Dermatological Practice; Immenstadt Germany
                [15 ]Allergy Unit; Department of Dermatology; University of Zurich; Zurich Switzerland
                [16 ]Christine Kühne Center for Allergy Research and Education CK-CARE; Davos Switzerland
                [17 ]Department Dermatology, Inselspital; Bern University Hospital; University of Bern; Bern Switzerland
                [18 ]Department of Dermatology; Heim Pál Children's Hospital; Budapest Hungary
                [19 ]Department of Dermatology, Venereology and Allergology; Wroclaw Medical University; Wroclaw Poland
                [20 ]Department of Dermatology and Pediatric Dermatology; Hôpital St André; Bordeaux France
                [21 ]Department of Dermatology; Hospital Niño Jesus; Madrid Spain
                [22 ]Department Dermatology and Allergy; Hannover Medical School; Hannover Germany
                [23 ]Department Dermatology and Allergy Biederstein; Technische Universität München; Munich Germany
                Article
                10.1111/jdv.14891
                29676534
                afe5c2e3-0631-442c-80a9-b1169fa02e26
                © 2018

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article